|
시장보고서
상품코드
1578148
세계의 의약품 첨가제 시장 규모, 성장률, 동향 분석 : 기능, 용도, 제품별 예측(-2032년)Global Pharmaceutical Excipients Market Size, Growth and Trends Analysis by Function, Application, Product - Industry Forecast 2032 |
||||||
의약품 첨가제 시장 규모는 2023년 92억 7,000만 달러, 2024년 100억 2,000만 달러에서 예측 기간 중 7.03%의 CAGR로 추이하며, 2032년에는 184억 8,000만 달러 규모로 성장할 것으로 예측됩니다.
다기능 첨가제에 대한 수요 증가와 제네릭 의약품의 사용 증가가 시장 확대의 주요 요인입니다.
의약품 첨가제는 특히 젊은 환자의 순응도를 높이기 위해 약의 맛을 향상시키는데도 사용됩니다. 의약품 첨가제는 화학 성분에 따라 유기물과 무기물 모두에서 얻을 수 있습니다. 기능성 첨가제에 대한 수요 증가, 최근 특허 만료, 나노 기술의 급속한 발전은 의약품 첨가제 시장을 촉진하는 주요 요인입니다. 첨가제는 장기 안정화, 최종 제형에서 활성 성분의 효능 강화 및 기타 목적을 위해 소량의 원료를 함유한 고체 제제에 첨가됩니다. 또한 첨가제는 원료 약물의 용해도를 높이고, 점도를 낮추고, 약물 흡수를 개선하는 등 의약품 제제의 특성을 개선하는 데에도 사용됩니다.
지역별 전망
유럽의 의약품 첨가제 시장은 2022년 25억 1,000만 달러 규모에 달할 것으로 예상되며, 상당한 CAGR로 성장할 것으로 전망됩니다. 의약품 특허 만료가 다가옴에 따라 많은 유럽 국가들이 제네릭 의약품 산업에 집중하고 있습니다. 독일, 영국, 프랑스와 같은 유럽 국가들은 예측 기간 중 눈에 띄는 성장률을 보일 것으로 예상됩니다. 의약품 첨가제는 이 지역에서 점점 더 많은 수요가 있을 것으로 예상됩니다.
북미는 제약 첨가제 시장에서 두 번째로 큰 점유율을 차지하고 있습니다. 예측 기간 중 제약 부문의 급속한 발전, 기능성 첨가제에 대한 수요 증가, 업계 선도 기업의 존재, 기술 발전 등으로 인해 시장이 크게 성장할 것으로 예상됩니다.
아시아태평양의 의약품 첨가제 시장은 2024-2032년 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
세계의 의약품 첨가제 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 개요
- 촉진요인
- 억제요인
- 기회
제5장 시장 요인 분석
- 밸류체인 분석
- Porter's Five Forces 분석
- COVID-19의 영향 분석
제6장 세계의 의약품 첨가제 시장 : 유형별
- 개요
- 의약품 충전제
- 바인더
- 코팅
- 붕괴제
- 방부제
- 기타
제7장 세계의 의약품 첨가제 시장 : 제품별
- 개요
- 유기 화학품
- 무기 화학품
제8장 세계의 의약품 첨가제 시장 : 용도별
- 개요
- 경구
- 국소
- 비경구
- 기타
제9장 세계의 의약품 첨가제 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제10장 기업 상황
- 개요
- 경쟁 분석
- 시장 점유율 분석
- 주요 성장 전략
- 경쟁 벤치마킹
- 개발수로 리드하는 기업
- 주요 개발·성장 전략
- 주요 기업의 재무 매트릭스
제11장 기업 개요
- EVONIK INDUSTRIES AG
- BASF SE
- FERRO CORPORATION
- P&G CHEMICALS
- FMC CORPORATION
- THE DOW CHEMICAL COMPANY
- ASHLAND, INC.
- CRODA INTERNATIONAL PLC
- AKZO NOBEL NV
- INNOPHOS
제12장 부록
KSA 24.11.01Global Pharmaceutical Excipients Market Size, Growth and Trends Analysis by Function (Pharmaceutical Fillers, Binders, Coatings, Disintegrants, Preservatives, Others), Application (Oral, Parenteral, Topical, Others), Product (Organic Chemicals, Inorganic Chemicals) - Industry Forecast 2032
Market Snapshot
The size of the pharmaceutical excipients market was estimated at USD 9.27 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 7.03% from 2024 to 2032, from USD 10.02 billion in 2024 to USD 18.48 billion by 2032. The growing need for multifunctional excipients and the growing use of generic drugs are the primary factors propelling market expansion.
Furthermore, the market for pharmaceutical excipients is used to enhance the medication's flavor, which increases patient compliance, especially in young patients. Pharmaceutical excipients can come from both organic and inorganic sources, depending on their chemical composition. The growing need for functional excipients, recent patent expirations that increase consumer demand for pharmaceutical excipients, and the rapid advancement of nanotechnology are the primary factors propelling the pharmaceutical excipients market. For long-term stabilization, to increase the potency of the active ingredient in the final dosage form, or for any other purpose, excipients can be added to solid formulations that contain small APIs. Additionally, excipients are used to improve the properties of medicinal formulations, including increasing API solubility, decreasing viscosity, and improving drug absorption.
Market Segments Insights
Pharmaceutical fillers, binders, coatings, disintegrants, preservatives, and others are among the market sectors for pharmaceutical excipients based on their operational roles.
By-products have been separated into organic and inorganic compounds according to market data for pharmaceutical excipients.
The pharmaceutical excipients market has been divided into several segments based on applications, including parenteral, topical, and oral.
Regional Perspectives
The market insights by region in the survey encompass Asia-Pacific, Europe, North America, and the rest of the globe. The pharmaceutical excipients market in Europe was estimated to be worth USD 2.51 billion in 2022 and was projected to grow at a significant compound annual growth rate. Many European nations concentrate on the generics industry because of the approaching expiration dates of pharmaceutical patents. Therefore, it is expected that European nations such as Germany, the United Kingdom, France, and others will have notable growth rates over the forecast period. Pharmaceutical excipients are expected to become more and more necessary in the region.
North America has the second-largest proportion of the pharmaceutical excipients market. Over the course of the projection period, the market is expected to increase significantly due to the quickly increasing pharmaceutical sector, rising demand for functional excipients, strong competitors in the industry, and technological advancements.
The Asia-Pacific pharmaceutical excipients market is projected to grow at the fastest compound annual growth rate (CAGR) from 2024 to 2032. According to a recent study, China's overall revenue from traditional pharmaceutical sales is expected to increase over the coming years.
Key Players
Evonik Industries Ag, Basf Se, Ferro Corporation, P&G Chemicals, Akzo Nobel NV, FMC Corporation, The Dow Chemical Company, Ashland, Inc., and Croda International PLC are a few of the major players in the pharmaceutical excipients industry.
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
- 2.1. DEFINITION
- 2.2. SCOPE OF THE STUDY
- 2.2.1. RESEARCH OBJECTIVE
- 2.2.2. ASSUMPTIONS
- 2.2.3. LIMITATIONS
3. RESEARCH METHODOLOGY
- 3.1. OVERVIEW
- 3.2. DATA MINING
- 3.3. SECONDARY RESEARCH
- 3.4. PRIMARY RESEARCH
- 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5. FORECASTING TECHNIQUE
- 3.6. MARKET SIZE ESTIMATION
- 3.6.1. BOTTOM-UP APPROACH
- 3.6.2. TOP-DOWN APPROACH
- 3.7. DATA TRIANGULATION
- 3.8. VALIDATION
4. MARKET DYNAMICS
- 4.1. OVERVIEW
- 4.2. DRIVERS
- 4.3. RESTRAINTS
- 4.4. OPPORTUNITIES
5. MARKET FACTOR ANALYSIS
- 5.1. VALUE CHAIN ANALYSIS
- 5.2. PORTER'S FIVE FORCES ANALYSIS
- 5.2.1. BARGAINING POWER OF SUPPLIERS
- 5.2.2. BARGAINING POWER OF BUYERS
- 5.2.3. THREAT OF NEW ENTRANTS
- 5.2.4. THREAT OF SUBSTITUTES
- 5.2.5. INTENSITY OF RIVALRY
- 5.3. COVID-19 IMPACT ANALYSIS
- 5.3.1. MARKET IMPACT ANALYSIS
- 5.3.2. REGIONAL IMPACT
- 5.3.3. OPPORTUNITY AND THREAT ANALYSIS
6. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE
- 6.1. OVERVIEW
- 6.2. PHARMACEUTICAL FILLERS
- 6.3. BINDERS
- 6.4. COATINGS
- 6.5. DISINTEGRANTS
- 6.6. PRESERVATIVES
- 6.7. OTHERS
7. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT
- 7.1. OVERVIEW
- 7.2. ORGANIC CHEMICALS
- 7.3. INORGANIC CHEMICALS
8. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY APPLICATION
- 8.1. OVERVIEW
- 8.2. ORAL
- 8.3. TOPICAL
- 8.4. PARENTERAL
- 8.5. OTHERS
9. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION
- 9.1. OVERVIEW
- 9.1. NORTH AMERICA
- 9.1.1. US
- 9.1.2. CANADA
- 9.2. EUROPE
- 9.2.1. GERMANY
- 9.2.2. FRANCE
- 9.2.3. UK
- 9.2.4. ITALY
- 9.2.5. SPAIN
- 9.2.6. REST OF EUROPE
- 9.3. ASIA-PACIFIC
- 9.3.1. CHINA
- 9.3.2. INDIA
- 9.3.3. JAPAN
- 9.3.4. SOUTH KOREA
- 9.3.5. AUSTRALIA
- 9.3.6. REST OF ASIA-PACIFIC
- 9.4. REST OF THE WORLD
- 9.4.1. MIDDLE EAST
- 9.4.2. AFRICA
- 9.4.3. LATIN AMERICA
10. COMPANY LANDSCAPE
- 10.1. OVERVIEW
- 10.2. COMPETITIVE ANALYSIS
- 10.3. MARKET SHARE ANALYSIS
- 10.4. MAJOR GROWTH STRATEGY IN THE GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET
- 10.5. COMPETITIVE BENCHMARKING
- 10.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET
- 10.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
- 10.7.1. NEW PRODUCT LAUNCH
- 10.7.2. MERGER & ACQUISITIONS
- 10.7.3. JOINT VENTURES
- 10.8. MAJOR PLAYERS FINANCIAL MATRIX
- 10.8.1. SALES & OPERATING INCOME,
- 10.8.2. MAJOR PLAYERS R&D EXPENDITURE.
11. COMPANY PROFILES
- 11.1. EVONIK INDUSTRIES AG
- 11.1.1. COMPANY OVERVIEW
- 11.1.2. FINANCIAL OVERVIEW
- 11.1.3. PRODUCT OFFERED
- 11.1.4. KEY DEVELOPMENTS
- 11.1.5. SWOT ANALYSIS
- 11.1.6. KEY STRATEGIES
- 11.2. BASF SE
- 11.2.1. COMPANY OVERVIEW
- 11.2.2. FINANCIAL OVERVIEW
- 11.2.3. PRODUCT OFFERED
- 11.2.4. KEY DEVELOPMENTS
- 11.2.5. SWOT ANALYSIS
- 11.2.6. KEY STRATEGIES
- 11.3. FERRO CORPORATION
- 11.3.1. COMPANY OVERVIEW
- 11.3.2. FINANCIAL OVERVIEW
- 11.3.3. PRODUCT OFFERED
- 11.3.4. KEY DEVELOPMENTS
- 11.3.5. SWOT ANALYSIS
- 11.3.6. KEY STRATEGIES
- 11.4. P&G CHEMICALS
- 11.4.1. COMPANY OVERVIEW
- 11.4.2. FINANCIAL OVERVIEW
- 11.4.3. PRODUCT OFFERED
- 11.4.4. KEY DEVELOPMENTS
- 11.4.5. SWOT ANALYSIS
- 11.4.6. KEY STRATEGIES
- 11.5. FMC CORPORATION
- 11.5.1. COMPANY OVERVIEW
- 11.5.2. FINANCIAL OVERVIEW
- 11.5.3. PRODUCT OFFERED
- 11.5.4. KEY DEVELOPMENTS
- 11.5.5. SWOT ANALYSIS
- 11.5.6. KEY STRATEGIES
- 11.6. THE DOW CHEMICAL COMPANY
- 11.6.1. COMPANY OVERVIEW
- 11.6.2. FINANCIAL OVERVIEW
- 11.6.3. PRODUCT OFFERED
- 11.6.4. KEY DEVELOPMENTS
- 11.6.5. SWOT ANALYSIS
- 11.6.6. KEY STRATEGIES
- 11.7. ASHLAND, INC.
- 11.7.1. COMPANY OVERVIEW
- 11.7.2. FINANCIAL OVERVIEW
- 11.7.3. PRODUCT OFFERED
- 11.7.4. KEY DEVELOPMENTS
- 11.7.5. SWOT ANALYSIS
- 11.7.6. KEY STRATEGIES
- 11.8. CRODA INTERNATIONAL PLC
- 11.8.1. COMPANY OVERVIEW
- 11.8.2. FINANCIAL OVERVIEW
- 11.8.3. PRODUCT OFFERED
- 11.8.4. KEY DEVELOPMENTS
- 11.8.5. SWOT ANALYSIS
- 11.8.6. KEY STRATEGIES
- 11.9. AKZO NOBEL NV
- 11.9.1. COMPANY OVERVIEW
- 11.9.2. FINANCIAL OVERVIEW
- 11.9.3. PRODUCT OFFERED
- 11.9.4. KEY DEVELOPMENTS
- 11.9.5. SWOT ANALYSIS
- 11.9.6. KEY STRATEGIES
- 11.10. INNOPHOS
- 11.10.1. COMPANY OVERVIEW
- 11.10.2. FINANCIAL OVERVIEW
- 11.10.3. PRODUCT OFFERED
- 11.10.4. KEY DEVELOPMENTS
- 11.10.5. SWOT ANALYSIS
- 11.10.6. KEY STRATEGIES
12. APPENDIX
- 12.1. REFERENCES
- 12.2. RELATED REPORTS
